RCKT stock forecast, quote, news & analysis
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company... Show more
Rocket Pharmaceuticals (RCKT) Stock Analysis: Pipeline Momentum Clashes with Mixed Analyst Sentiment
Key Takeaways
- Rocket Pharmaceuticals shares traded near $3.21 in late July 2026, reflecting a modest pullback of roughly 1.2% over the trailing 30-day period despite a pronounced mid-month rally that briefly pushed the stock above $4.20.
- The company secured FDA accelerated approval for KRESLADI™ in March 2026 and subsequently monetized a Rare Pediatric Disease Priority Review Voucher for $180 million, extending its cash runway into the second quarter of 2028.
- Analyst sentiment remains divided, with price targets ranging from $3 (Goldman Sachs, Sell) to $16 (Wedbush, Outperform), while the consensus rating sits at Hold with an average target near $8.88.
- The pivotal Phase 2 trial of RP-A501 for Danon disease is actively dosing patients, and a critical program update is expected in the second half of 2026.
- Q2 2026 earnings are anticipated around August 6, with investors watching for pipeline progress updates and any changes to cash-burn guidance.
Current Market Snapshot
Rocket Pharmaceuticals (RCKT) has experienced a volatile stretch in recent weeks, with shares climbing from approximately $3.25 in late June to an intra-period peak of $4.24 on July 8 before retreating back toward the $3.20 level. The sharp mid-July rally coincided with a period of heightened investor interest in gene therapy names, but profit-taking and a subsequent analyst downgrade from Wall Street Zen—which moved the stock from Hold to Sell on July 18—contributed to a swift reversal. The broader biotech sector has faced headwinds from macroeconomic uncertainty and a risk-off tilt among institutional allocators, which has weighed disproportionately on pre-revenue and early-commercial-stage companies. Despite the pullback, RCKT's underlying fundamentals have improved meaningfully year-to-date, anchored by a fortified balance sheet and tangible regulatory progress.
Rocket Pharmaceuticals (RCKT) Business Overview and Competitive Position
Rocket Pharmaceuticals is a fully integrated, commercial-stage biotechnology company advancing a pipeline of gene therapies for rare and devastating diseases. The company's lead programs target inherited cardiovascular conditions, including Danon disease (RP-A501 in Phase 2), PKP2 arrhythmogenic cardiomyopathy (RP-A601 in Phase 1), and BAG3-associated dilated cardiomyopathy (RP-A701, preparing for first-in-human dosing). Rocket also received FDA accelerated approval in March 2026 for KRESLADI™, the first gene therapy for severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients. The company operates proprietary in-house AAV manufacturing capabilities from its Cranbury, New Jersey facility—a strategic asset that differentiates it from competitors reliant on contract manufacturing organizations. With pro forma cash of approximately $322.6 million following the $180 million PRV sale, Rocket's operational runway extends into Q2 2028, reducing near-term dilution risk.
Recent Developments Driving RCKT
Several verified catalysts have shaped RCKT's narrative over the past 30 days. On June 10, Rocket closed the $180 million sale of its Rare Pediatric Disease Priority Review Voucher, a non-dilutive capital infusion that meaningfully de-risked the balance sheet. The pivotal Phase 2 trial of RP-A501 for Danon disease continues to dose patients at a recalibrated level following the FDA's earlier clinical hold resolution, with management signaling a program update in the second half of 2026. On the analyst front, Bank of America raised its price target to $9 while maintaining a Buy rating, and Wedbush reiterated its Outperform rating with a $16 target. Conversely, Wall Street Zen downgraded RCKT to Sell on July 18, and Goldman Sachs maintained its Sell rating with a $3 target. CEO Gaurav Shah sold 55,684 shares in May—a transaction disclosed in SEC filings as related to tax obligations from vesting equity awards. The stock also saw insider selling totaling 83,733 shares over 90 days, though insider ownership remains significant at approximately 21%.
Trending AI Robots
Tickeron's Trending AI Robots page offers traders a curated view into a universe of hundreds of AI-powered trading bots actively trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, making it a practical starting point for investors seeking algorithmically driven insights. Bots vary widely in strategy—from swing trading and trend following to mean reversion and breakout models—and operate across different timeframes and performance benchmarks. Each bot's track record, win rate, and recent trades are transparently displayed, allowing users to evaluate alignment with their own risk tolerance and investment goals. Exploring the Trending AI Robots page can help investors identify data-driven tools that complement traditional fundamental research.
2026 Outlook and What Investors Should Watch
Looking ahead, several milestones could define RCKT's trajectory through the remainder of 2026. The Q2 2026 earnings report, expected around August 6, will provide a critical update on R&D spending, cash burn, and pipeline timelines. Investors will be listening closely for any commentary on enrollment progress in the Danon disease pivotal trial and the anticipated first-patient dosing for the BAG3-DCM Phase 1 study. Regulatory engagement with the FDA on the PKP2-ACM pivotal trial design also remains a key catalyst. On the commercial side, the planned Q4 2026 launch of KRESLADI at select specialized treatment centers represents Rocket's first foray into product revenue, though management has characterized the opportunity as modest given the ultra-rare patient population. Risks include potential clinical trial setbacks, broader biotech sector weakness, and the possibility that the Danon disease update in the second half of 2026 underwhelms investor expectations. With analyst price targets spanning a wide $3 to $16 range, the stock reflects both the high upside of successful gene therapy execution and the inherent uncertainty of clinical-stage biotechnology.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RCKT in upward trend: 10-day moving average moved above 50-day moving average on June 30, 2026
The 10-day moving average for RCKT crossed bullishly above the 50-day moving average on June 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 135 cases where RCKT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for RCKT moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCKT as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RCKT turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
RCKT moved below its 50-day moving average on July 24, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RCKT broke above its upper Bollinger Band on July 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.470) is normal, around the industry mean (19.732). P/E Ratio (0.000) is within average values for comparable stocks, (38.804). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.750). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (423.664).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of gene therapy services
Industry Biotechnology